JACC:BARC出血标准在急性冠脉综合征患者中得到成功验证

2016-05-03 MedSci MedSci原创

出血学术研究会(BARC)已经提出要在心血管临床试验中规范出血终点定义和报告。大型患者队列验证是必要的。本研究旨在调查BARC归类出血和死亡率之间的关系,并比较了其预后价值与2个验证出血级别:TIMI(心肌梗死溶栓)和GUSTO(打开闭塞动脉的全球策略使用)之间的关系。研究人员分析了12944例无ST段抬高急性冠脉综合征患者的出血情况,有或没有早期介入治疗。主要观察指标是全因死亡。在随访期间(平均

出血学术研究会(BARC)已经提出要在心血管临床试验中规范出血终点定义和报告。大型患者队列验证是必要的。

本研究旨在调查BARC归类出血和死亡率之间的关系,并比较了其预后价值与2个验证出血级别:TIMI(心肌梗死溶栓)和GUSTO(打开闭塞动脉的全球策略使用)之间的关系。

研究人员分析了12944例无ST段抬高急性冠脉综合征患者的出血情况,有或没有早期介入治疗。主要观察指标是全因死亡。

在随访期间(平均:502天),根据BARC(等级2,3或5),1998(15.4%)例患者发生非冠状动脉搭桥(CABG)出血,根据TIMI轻微/重大标准,484(3.7%)例患者发生出血,根据GUSTO中度/重度的标准,514(4.0%)例患者发生出血。155(1.2%)例患者发生CABG相关的出血(BARC 4)。与无出血患者(BARC 0或1)相比,BARC(2,3,或4)患者出血死亡的风险显著增加;出血后30天危险最高(危险比:7.35; 95%可信区间:5.59至9.68; P<0.0001),并显著保持长达1年。死亡的危险性随着非CABG BARC等级的增加而逐渐增加。BARC 4出血均与30天内死亡显著相关(危险比:10.05; 95%置信区间:5.41至18.69,P<0.0001),但此后并没有相关性。拥有基线特征的1年死亡模型中纳入BARC(2,3或4)出血可将其改善至与TIMI轻微/重大和GUSTO中度/重度出血的程度相当。

在无ST段抬高急性冠脉综合征患者中,使用BARC规模可评估出血与随后死亡的显著相关性,并长达事件后1年,死亡风险随着BARC的逐渐增加而增加。该研究结果支持ACS临床试验采用BARC出血规模进行评估。

原始出处:

Pascal Vranckx,Harvey D. White,Zhen Huang,et al.Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes,JACC,2016.5.3

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853521, encodeId=5b5e1853521be, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 08 14:36:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985231, encodeId=9e7e19852315c, content=<a href='/topic/show?id=49793198ec' target=_blank style='color:#2F92EE;'>#BARC出血标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3198, encryptionId=49793198ec, topicName=BARC出血标准)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Thu Dec 15 12:36:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780281, encodeId=bef81e802816f, content=<a href='/topic/show?id=e919319619' target=_blank style='color:#2F92EE;'>#BARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3196, encryptionId=e919319619, topicName=BARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 31 17:36:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325234, encodeId=b72c132523487, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430613, encodeId=0e2314306135e, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84220, encodeId=91a184220ed, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Wed May 04 19:07:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-07-08 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853521, encodeId=5b5e1853521be, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 08 14:36:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985231, encodeId=9e7e19852315c, content=<a href='/topic/show?id=49793198ec' target=_blank style='color:#2F92EE;'>#BARC出血标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3198, encryptionId=49793198ec, topicName=BARC出血标准)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Thu Dec 15 12:36:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780281, encodeId=bef81e802816f, content=<a href='/topic/show?id=e919319619' target=_blank style='color:#2F92EE;'>#BARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3196, encryptionId=e919319619, topicName=BARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 31 17:36:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325234, encodeId=b72c132523487, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430613, encodeId=0e2314306135e, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84220, encodeId=91a184220ed, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Wed May 04 19:07:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853521, encodeId=5b5e1853521be, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 08 14:36:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985231, encodeId=9e7e19852315c, content=<a href='/topic/show?id=49793198ec' target=_blank style='color:#2F92EE;'>#BARC出血标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3198, encryptionId=49793198ec, topicName=BARC出血标准)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Thu Dec 15 12:36:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780281, encodeId=bef81e802816f, content=<a href='/topic/show?id=e919319619' target=_blank style='color:#2F92EE;'>#BARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3196, encryptionId=e919319619, topicName=BARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 31 17:36:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325234, encodeId=b72c132523487, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430613, encodeId=0e2314306135e, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84220, encodeId=91a184220ed, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Wed May 04 19:07:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-31 yangfl06
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853521, encodeId=5b5e1853521be, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 08 14:36:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985231, encodeId=9e7e19852315c, content=<a href='/topic/show?id=49793198ec' target=_blank style='color:#2F92EE;'>#BARC出血标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3198, encryptionId=49793198ec, topicName=BARC出血标准)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Thu Dec 15 12:36:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780281, encodeId=bef81e802816f, content=<a href='/topic/show?id=e919319619' target=_blank style='color:#2F92EE;'>#BARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3196, encryptionId=e919319619, topicName=BARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 31 17:36:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325234, encodeId=b72c132523487, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430613, encodeId=0e2314306135e, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84220, encodeId=91a184220ed, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Wed May 04 19:07:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853521, encodeId=5b5e1853521be, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 08 14:36:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985231, encodeId=9e7e19852315c, content=<a href='/topic/show?id=49793198ec' target=_blank style='color:#2F92EE;'>#BARC出血标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3198, encryptionId=49793198ec, topicName=BARC出血标准)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Thu Dec 15 12:36:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780281, encodeId=bef81e802816f, content=<a href='/topic/show?id=e919319619' target=_blank style='color:#2F92EE;'>#BARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3196, encryptionId=e919319619, topicName=BARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 31 17:36:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325234, encodeId=b72c132523487, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430613, encodeId=0e2314306135e, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84220, encodeId=91a184220ed, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Wed May 04 19:07:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853521, encodeId=5b5e1853521be, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Fri Jul 08 14:36:00 CST 2016, time=2016-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985231, encodeId=9e7e19852315c, content=<a href='/topic/show?id=49793198ec' target=_blank style='color:#2F92EE;'>#BARC出血标准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3198, encryptionId=49793198ec, topicName=BARC出血标准)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Thu Dec 15 12:36:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780281, encodeId=bef81e802816f, content=<a href='/topic/show?id=e919319619' target=_blank style='color:#2F92EE;'>#BARC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3196, encryptionId=e919319619, topicName=BARC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Tue May 31 17:36:00 CST 2016, time=2016-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325234, encodeId=b72c132523487, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430613, encodeId=0e2314306135e, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu May 05 12:36:00 CST 2016, time=2016-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=84220, encodeId=91a184220ed, content=不错的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9ebb1716792, createdName=黑心天使, createdTime=Wed May 04 19:07:00 CST 2016, time=2016-05-04, status=1, ipAttribution=)]
    2016-05-04 黑心天使

    不错的研究

    0

相关资讯

JACC:阿哌沙班单抗或双重抗血小板治疗急性冠脉综合征效果

    目前,出血情况限制了急性冠脉综合征(ACS)的抗凝治疗。该研究对ACS后伴随抗血小板治疗是否会影响阿哌沙班的效果进行了调查。    本研究旨在探讨使用阿司匹林或阿司匹林加氯吡格雷治疗的高危急性冠脉综合征患者被随机分配接受每日两次阿哌沙班5毫克或安慰剂的效果。在事后分析中,研究人员评估是否阿哌沙班的疗效和安全性会随着伴随抗血小板方案的使用而变化,通过有

BMJ Open:男性易发生不稳定型心绞痛

不稳定型心绞痛,是介于劳累性稳定型心绞痛与急性心肌梗死和猝死之间的临床表现。主要包括初发心绞痛、恶化劳力性心绞痛、静息心绞痛伴心电图缺血改变和心肌梗死后早期心绞痛。其特征是心绞痛症状进行性增加,新发作的休息或夜间性心绞痛或出现心绞痛持续时间延长。研究者在芬兰进行了一项基于人群的回顾性研究,探究因不稳定型心绞痛(UAP)的住院率的性别差异和年龄差异。该研究纳入了2000年5月-2009年10月间、≥

BMJ Open:急性冠脉综合征患者临床特征、处理及1年预后

目的:评估伊朗急性冠脉综合征住院(ACS)患者的特征,管理及出院1年后的预后。设置:伊朗伊斯兰共和国5个主要城市的11家三级医疗医院。参与者:年龄≥20和≤80岁的出院确诊为ACS的患者,包括ST段抬高心肌梗死(STEMI)、非ST段抬高型心肌梗死(NSTEMI)和高危不稳定型心绞痛(HR-UA)。主要和次要结果措施:随访患者,药物的应用和研究的终点为出院后1个月和1年的终点。该研究的主要终点是出

依折麦布药物或降低急性冠脉综合征患者的发病率!

依折麦布可降低糖尿病患者和急性冠脉综合征患者的心血管疾病的发病率,根据布莱根妇女医院的心内科医生Robert Giugliano博士进行的IMPROVE-IT试验指出,依折麦布比单独使用他汀类药物降低低密度脂蛋白胆固醇的效果更好,从而可降低糖尿病患者心脑血管事件发生的风险。“急性冠脉综合征,包括心肌梗塞和不稳定型心绞痛(心梗先兆),是世界各地民众死亡和心功能不全的主要原因,”Robert Giug

NEJM:lixisenatide不能改变急性冠状动脉综合征合并2型糖尿病患者不良预后

背景:2型糖尿病患者,心血管疾病的发病率和死亡率较高,尤其是那些有心血管疾病的患者。研究者评估了胰高血糖素样肽1受体激动剂,利西拉肽对最近发生急性冠脉疾病的2型糖尿病患者心血管预后的影响。方法:研究者随机将180天内出现心肌梗死或不稳定心绞痛患者接受lixisenatide或安慰剂治疗,两组都进行当地的标准化护理。该试验有足够的统计效力评估lixisenatide优于或劣于安慰剂,即主要的复合终点

AIM:急性冠脉综合征(ACSs),早期介入治疗效果更好

随机临床试验发现,对于急性冠脉综合征(ACSs),与保守微创方法相比,早期介入治疗策略降低死亡率,心肌梗死(MI)和再住院概率,但这样的策略在现实生活中的设置的效果是未知的。该研究的目的是探讨早期 vs 保守的介入治疗对于ACSs患者的心血管不良后果。在该前瞻性队列研究中,研究人员的数据来自于ACSs患者接受所有急性介入治疗的数据,以及来自丹麦国家登记处住院,手术及结果的行政卫生保健数据。参与者为